Study 9 of 9TB-500 Ac-LKKTETQ literatureNatureTop journal2007

Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization.

Not reported in abstract.

Read at Nature Add to compare

Where it sits

this study against the rest of the tb-500 ac-lkktetq corpus

Preclinical · this one

Observational

Open-label

Randomised

Reviews

Summary and findings

Not reported in abstract.

How much of this paper we could read: title only (0.10). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →

2007

Abstract

The authors’ words, as Nature supplied them

Cardiac failure has a principal underlying aetiology of ischaemic damage arising from vascular insufficiency. Molecules that regulate collateral growth in the ischaemic heart also regulate coronary vasculature formation during embryogenesis. Here we identify thymosin beta4 (Tbeta4) as essential for all aspects of coronary vessel development in mice, and demonstrate that Tbeta4 stimulates significant outgrowth from quiescent adult epicardial explants, restoring pluripotency and triggering differentiation of fibroblasts, smooth muscle cells and endothelial cells. Tbeta4 knockdown in the heart is accompanied by significant reduction in the pro-angiogenic cleavage product N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP). Although injection of AcSDKP was unable to rescue Tbeta4 mutant hearts, it significantly enhanced endothelial cell differentiation from adult epicardially derived precursor cells. This study identifies Tbeta4 and AcSDKP as potent stimulators of coronary vasculogenesis and angiogenesis, and reveals Tbeta4-induced adult epicardial cells as a viable source of vascular progenitors for continued renewal of regressed vessels at low basal level or sustained neovascularization following cardiac injury.

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the TB-500 Ac-LKKTETQ corpus

BRising Use of Unapproved BPC-157 (“Wolverine Peptide”) and Associated Patient-Reported Outcomes Curated from Clinical Notesbiorxiv-preprint · 2023 · n=1536 · 33-fold increase in newly confirmed users between 2020 and 2026.Human BCo-creating a community health research agenda with a youth advisory group in rural Cambodia: process, involvement, and outcomesbiorxiv-preprint · 2026 · Diabetes ranked 9.1/10 in concern.Human BEffect of transitioning virally suppressed children and adolescents with HIV to dolutegravir-based antiretroviral therapy: emulated target trials in a large cohort in South Africabiorxiv-preprint · 2026 · RD -5·2 [95% CI -5·8 to -4·6]Human BDeep sequencing reveals subpopulation dynamics associated with treatment failure in a rare non-tuberculous mycobacterial infectionbiorxiv-preprint · 2026 · 444 unique SNPs identified in 12 longitudinal isolates.Human BFrom sample to insight: Onsite training and implementing mobile environmental surveillance in sub-Saharan Africabiorxiv-preprint · 2026 · 83 samples sequenced using long-read metagenomic sequencing.Human BInherited human TFIIIA deficiency disrupts T cell developmentbiorxiv-preprint · 2026 · Not reported in abstract.Human